• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics and Personalized Medicine >UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
【24h】

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

机译：UGT1A1基因多态性在癌症中：对伊立替康治疗的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mutations in the UGT1A1 gene have been implicated in Gilbert syndrome, which shows mild hyperbilirubinemia, and a more aggressive childhood subtype, Crigler–Najjar syndrome. To date, more than 100 variants have been found in the UGT1A1 gene. Among them, UGT1A1 * 28 and UGT1A1 * 6 have been reported to be associated with severe toxicities in patients treated with irinotecan-based chemotherapy by increasing the dose of SN-38 (7-ethyl-10-hydroxycamptothecin), an active form of irinotecan. Many association studies and meta-analyses have demonstrated the contribution of UGT1A1 * 28 and UGT1A1 * 6 polymorphisms to the toxicities caused by irinotecan-based therapy. The aim of this review was to evaluate the impact of these variants upon the toxicities and the efficacy of irinotecan-based chemotherapy.
机译：UGT1A1基因的突变与吉尔伯特综合征有关，吉尔伯特综合征表现为轻度高胆红素血症，童年时期的亚型为Crigler-Najjar综合征。迄今为止，已在UGT1A1基因中发现了100多个变体。其中，通过增加伊立替康的活性形式SN-38（7-乙基-10-羟基喜树碱）的剂量，已报道UGT1A1 * 28和UGT1A1 * 6与基于伊立替康的化疗患者的严重毒性相关。许多关联研究和荟萃分析表明，UGT1A1 * 28和UGT1A1 * 6多态性对以伊立替康为基础的治疗所致毒性的影响。这篇综述的目的是评估这些变体对基于伊立替康的化学疗法的毒性和功效的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号